When you see Jay's tumor shrink, his hope for a father-daughter dance grows
Confidence in choosing the right cancer treatment for your patient comes from seeing results. Experience and data have shown ERBITUX with FOLFIRI (irinotecan, fluorouracil, and leucovorin) can deliver the real, tangible results you need to see for appropriate patients with KRAS wild-type, EGFR-expressing metastatic colorectal cancer (mCRC). Because when you see results, your patient sees hope.
Metastatic Colorectal Cancer
ERBITUX is indicated for the treatment of KRAS wild-type, epidermal growth factor receptor (EGFR)-expressing, metastatic colorectal cancer (mCRC) as determined by an FDA-approved test for this use:
- In combination with FOLFIRI (irinotecan, fluorouracil, leucovorin) for first-line treatment
- In combination with irinotecan in patients who are refractory to irinotecan-based chemotherapy
- As a single agent in patients who have failed oxaliplatin- and irinotecan-based chemotherapy or who are intolerant to irinotecan
Limitations of Use: ERBITUX is not indicated for treatment of RAS-mutant colorectal cancer or when the results of the RAS mutation tests are unknown.